FDA Approves GSK’s Hibsago for Chronic Hepatitis B
The FDA approved Hibsago (bepirovirsen) for chronic hepatitis B in adults receiving nucleos(t)ide analogue reverse transcriptase inhibitor therapy.
Story updates
11:58:31 PM UTC
SquawkNews
GSK plc said the FDA approved Hibsago (bepirovirsen) for use with NrtI therapy in certain adult chronic hepatitis B patients without cirrhosis and with HBsAg ≤3000 IU/mL, after at least 6 months of NrtI and suppressed HBV DNA.Material DetailsContext by AI AnalystThis is a late-stage milestone that…
GSK plc (LSE/NYSE:GSK) today announced that the US Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients withou…